9th Orphan Drugs and Rare Diseases Global Congress 2019 Europe

London, UK

In the United States, a rare disease is defined as a condition affecting fewer than 200,000 people. In EU countries, any disease affecting fewer than 1 in 2,000 people is considered rare. That number may seem small, but it translates into approximately 246 000 people throughout the EU’s 28 member countries. Most patients suffer from even rarer diseases affecting 1 person in 100,000 or more.

 

There are more than 7,000 rare diseases identified, however, only a fraction of them have approve treatment available. “Orphan drugs” are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions. Currently, the regulatory climate is favourable with both FDA and European Medicines Agency, as they offer incentives, tax credits, user waivers and marketing exclusivity. As a result, the number of therapies approved for rare diseases for the past two decades has grown exponentially.

 

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases 2019 Europe. It’s the 9th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

 

In EU countries, any disease affecting fewer than 1 in 2,000 people is considered rare. That number may seem small, but it translates into approximately 246 000 people throughout the EU’s 28 member countries. Most patients suffer from even rarer diseases affecting 1 person in 100,000 or more.

 

There are more than 7,000 rare diseases identified, however, only a fraction of them have approve treatment available. “Orphan drugs” are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions. Currently, the regulatory climate is favourable with both FDA and European Medicines Agency, as they offer incentives, tax credits, user waivers and marketing exclusivity. As a result, the number of therapies approved for rare diseases for the past two decades has grown exponentially.

 

The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing and more.

The two-day Congress will provide an interactive, cutting edge and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.

 

Who will you meet

 

This congress is specially created for valued stakeholders in the Rare Disease community: Presidents, Heads/Chiefs, Directors, VPs and Managers in the are of:

 

Research and Development, Personalised Medicine, Regenerative Medicine, External R&D Innovation, Innovative Medicine, Rare and Ultra-Rare Diseases, Therapeutic Are Lead, Cell and Gene Therapy, Translational Science, Molecular Geneticist, Program Management, Patient Advocacy Groups, Patient Engagement, Public Affairs, Medical Affairs, Regulatory Affairs, Clinical Research Organizations, Market Access, Managed and Early Access, Pricing and Reimbursement, Health Economics Outcomes Research, Commercial Development, Investments and Funding, Product Specialist, Global Strategic Services, Business Planning and Operations , Speciality Pharmacies, Academia

 

By attending you will learn:

  • What is Orphan Drugs’ role in sustainability of the Pharmaceutical Industry?
  • Finding innovative and alternative ways in funding the development of Orphan Drugs
  • How commercially viable Is It to Engage in the Development of Orphan Drugs?
  • What Do Developers Look for When Looking for an Outsourcing Partner?
  • Coming Together in Developing Orphan Drugs and Crossing Borders
  • Trends and Deal Structures in Licensing Agreements
  • How Can the Developer and the Patient Assist in the Evolution and Development of Orphan Drugs?
  • Patient Access: How Can This Continue to Improve?
  • What Do Insurance Companies Think About Orphan Drugs? Will They Make Modifications to Their Policies to Support Patients with Rare Diseases?

Previous Conference Gallery

Orphan Drugs & Rare Diseases 2019

ADD THIS EVENT TO YOUR CALENDAR

Windows   Apple   Google

Sponsors

Our Partners

To Sponsor/Exhibit

To Speak

To Register

sponsor@paradigmglobalevents.com
Tel. +44 203 567 1321

jocelynr@paradigmglobalevents.com
Tel. +44 203 567 1321

booking@paradigmglobalevents.com
Tel. +44 203 567 1321